BIM 28011

Drug Profile

BIM 28011

Latest Information Update: 04 May 2007

Price : $50

At a glance

  • Originator Biomeasure Inc
  • Class Growth factors; Hormones
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Dwarfism; Skin ulcer; Turner's syndrome

Most Recent Events

  • 12 Sep 2000 No-Development-Reported for Skin ulcer in France (Unknown route)
  • 12 Sep 2000 No-Development-Reported for Turner's syndrome in France (Unknown route)
  • 29 Apr 1997 Phase-I clinical trials for Turner's syndrome in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top